Transforming growth factor-β1 variant Leu10Pro is associated with both lack of microfilariae and differential microfilarial loads in the blood of persons infected with lymphatic filariasis

Human Immunology

Volumn 72, Issue 11, 2011, Pages 1143-1148

  Debrah, Alexander Yaw ^a,b   Batsa, Linda ^b   Albers, Anna ^c   Mand, Sabine ^c   Toliat, Mohammad Reza ^d   Nürnberg, Peter ^d   Adjei, Ohene ^b   Hoerauf, Achim ^c   Pfarr, Kenneth ^c  

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^b KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Lymphatic filariasis; Microfilaria; Single nucleotide polymorphism; TGF 1; Wuchereria bancrofti

Indexed keywords

LEUCINE; PROLINE; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GHANA; HAPLOTYPE; HUMAN; HYDROCELE; IMMUNOGENETICS; LYMPHATIC FILARIASIS; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MICROFILARIA (NEMATODE LARVA); MICROFILARIASIS; PARASITE LOAD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; WUCHERERIA BANCROFTI;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, HELMINTH; DISEASE PROGRESSION; ELEPHANTIASIS, FILARIAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GHANA; HUMANS; MALE; MICROFILARIA; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; WUCHERERIA BANCROFTI;

EID: 80054118621     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.07.305     Document Type: Article

References (50)

1. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 2006, 81:221-232. World Health Organization.
2. Meeting of the International Task Force for Disease Eradication. Wkly Epidemiol Rec 2007, 82:197-202. World Health Organization.
3. Maizels R.M., Sartono E., Kurniawan A., Partono F., Selkirk M.E., Yazdanbakhsh M. T-cell activation and the balance of antibody isotypes in human lymphatic filariasis. Parasitol Today 1995, 11:50-56.
4. Tisch D.J., Hazlett F.E., Kastens W., Alpers M.P., Bockarie M.J., Kazura J.W. ECOLOGIC and biologic determinants of filarial antigenemia in bancroftian filariasis in Papua New Guinea. J Infect Dis 2001, 184:898-904.
5. Ottesen E. Immunopathology of lymphatic filariasis in man. Springer Semin Immunopathol 1980, 2:373-385.
6. Hoerauf A., Kruse S., Brattig N.W., Heinzmann A., Mueller-Myhsok B., Deichmann K.A. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002, 4:37-42.
7. Terhell A.J., Houwing-Duistermaat J.J., Ruiterman Y., Haarbrink M., Abadi K., Yazdanbakhsh M. Clustering of Brugia malayi infection in a community in South-Sulawesi, Indonesia. Parasitology 2000, 120:23-29.
8. Cuenco K.T., Halloran M.E., Lammie P.J. Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004, 70:185-190.
9. Cuenco K.T., Halloran M.E., Louis-Charles J., Lammie P.J. A family study of lymphedema of the leg in a lymphatic filariasis-endemic area. Am J Trop Med Hyg 2004, 70:180-184.
10. Wahyuni S., Houwing-Duistermaat J.J., Syafruddin, Supali T., Yazdanbakhsh M., Sartono E. Clustering of filarial infection in an age-graded study: genetic, household and environmental influences. Parasitology 2004, 128:315-321.
11. Debrah A.Y., Mand S., Toliat M.R., Marfo-Debrekyei Y., Batsa L., NÜrnberg P., et al. Plasma vascular endothelial growth factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis. Am J Trop Med Hyg 2007, 77:601-608.
12. Cuenco K.T., Ottesen E.A., Williams S.A., Nutman T.B., Steel C. Heritable factors play a major role in determining host responses to Wuchereria bancrofti infection in an isolated South Pacific island population. J Infect Dis 2009, 200:1271-1278.
13. Wattal S., Dhariwal A.C., Ralhan P.K., Tripathi V.C., Regu K., Kamal S., et al. Evaluation of Og4C3 antigen ELISA as a tool for detection of bancroftian filariasis under lymphatic filariasis elimination programme. J Commun Disord 2007, 39:75-84.
14. Pani S.P., Hoti S.L., Vanamail P., Das L.K. Comparison of an immunochromatographic card test with night blood smear examination for detection of Wuchereria bancrofti microfilaria carriers. Natl Med J India 2004, 176:304-306.
15. Wenk P., Wegerhof P.H. Studies on acquired resistance of the cotton rat against microfilariae of Litomosoides carinii. 2. Injection of microfilariae during prepatency. Z Parasitenkd 1982, 68:321-329.
16. Brattig N.W., Lepping B., Timmann C., BÜttner D.W., Marfo Y., Hamelmann C., et al. Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density. J Infect Dis 2002, 185:1148-1154.
17. Specht S., Volkmann L., Wynn T., Hoerauf A. Interleukin-10(IL-10) counterregulates IL-4-dependent effector mechanisms in Murine filariasis. Infect Immun 2004, 72:6287-6293.
18. Volkmann L., Bain O., Saeftel M., Specht S., Fischer K., Brombacher F., et al. Murine filariasis: interleukin 4 and interleukin 5 lead to containment of different worm developmental stages. Med Microbiol Immunol 2003, 192:23-31.
19. Doetze A., Satoguina J., Burchard G., Rau T., LÖliger C., Fleischer B., et al. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol 2000, 12:623-630.
20. Satoguina J., Mempel M., Larbi J., Badusche M., LÖliger C., Adjei O., et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002, 4:1291-1300.
21. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999, 8:93-97.
22. Wrann M., Bodmer S., de Martin R., Siepl C., Hofer-Warbinek R., Frei K., et al. T-cell suppressor factor from human glioblastoma cells is a 12.5 kDa protein closely related to the transforming growth factor-b. EMBO J 1987, 6:1633-1636.
23. de Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann M., SchlÜsener H., Seifert J.M., Bodmer S., Fontana A., Hofer E. Complementary DNA for human glioblastoma-derived T-cell suppressor factor, a novel member of the transforming growth factor-b gene family. EMBO J 1987, 6:3673-3677.
24. Ignotz R.A., Massaguê J. Transforming growth factor-b stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986, 261:4337-4345.
25. Ignotz R.A., Massaguê J. Cell adhesion receptors as targets for transforming growth factor-b action. Cell 1987, 51:189-197.
26. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1995, 1:282-284.
27. Pierce D.F., Gorska A.E., Chytil A., Meise K.S., Page D.L., Coffey R.J., et al. Mammary tumour suppression by TGF-β1 transgene expression. Proc Natl Acad Sci U S A 1995, 92:4254-4258.
28. Grainger D.J., Kemp P.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1995, 1:74-79.
29. McCartney-Francis N., Jin W., Wahl S.M. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-β 1 signaling pathway. J Immunol 2004, 172:3814-3821.
30. Debrah A.Y., Mand S., Specht S., Marfo-Debrekyei Y., Batsa L., Pfarr K., et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006, 2:e92.
31. Ronaghi M., Karamohamed S., Pettersson B., Uhlên M., Nyrên P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 1996, 242:84-89.
32. Dempster A.P., Laird N.M., Rubin D.B. Maximum Likelihood from Incomplete Data via the EM Algorithm. J R Stat Soc B Stat Methodol 1977, 39:38.
33. Herold C., Becker T. Genetic association analysis with FAMHAP: a major program update. Bioinformatics 2009, 25:134-136.
34. Becker T., Cichon S., JÖnson E., Knapp M. Multiple testing in the context of haplotype analysis revisited: application to case-control data. Ann Hum Genet 2005, 69:747-756.
35. Yokota M., Ichihara S., Lin T.L., Nakashima N., Yamada Y. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101:2783-2787.
36. Dunning A.M., Ellis P.D., McBride S., Kirschenlohr H.L., Healey C.S., Kemp P.R., et al. A transforming growth factor beta-1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003, 63:2610-2615.
37. Massaguê J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6:597-641.
38. Mustoe T.A., Pierce G.F., Thomason A., Gramates P., Sporn M.B., Deuel T.F. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 1987, 237:1333-1336.
39. Colletta A.A., Wakefield L.M., Howell F.V., Danielpour D., Baum M., Sporn M.B. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 1991, 87:277-283.
40. Pfarr K.M., Debrah A.Y., Specht S., Hoerauf A. Filariasis and lymphoedema. Parasite Immunol 2009, 31:664-672.
41. Hoerauf A., Satoguina J., Saeftel M., Specht S. Immunomodulation by filarial nematodes. Parasite Immunol 2005, 27:417-429.
42. Specht S., Volkmann L., Wynn T., Hoerauf A. Interleukin-10(IL-10) counterregulates IL-4-dependent effector mechanisms in murine filariasis. Infect Immun 2004, 72:6287-6293.
43. Greene B.M., Fanning M.M., Ellner J.J. Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man. Clin Exp Immunol 1983, 52:259-265.
44. Elson L.H., Calvopiña M., Paredes W., Araujo E., Bradley J.E., Guderian R.H., et al. Immunity to onchocerciasis: putative immune persons produce a Th1-like response to Onchocerca volvulus. J Infect Dis 1995, 171:652-658.
45. + T cells from putatively immune individuals. Int Immunol 1997, 9:721-729.
46. King C.L., Mahanty S., Kumaraswami V., Abrams J.S., Regunathan J., Jayaraman K., et al. Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset. J Clin Invest 1993, 92:1667-1673.
47. Mahanty S., Nutman T.B. Immunoregulation in human lymphatic filariasis: The role of interleukin 10. Parasite Immunol 1995, 17:385-392.
48. Henry N.L., Law M., Nutman T.B., Klion A.D. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. J Infect Dis 2001, 183:512-516.
49. Hoerauf A., Brattig N. Resistance and susceptibility in human onchocerciasis-beyond Th1 vs. Th2. Trends Parasitol 2002, 18:25-31.
50. Maizels R.M., Balic A., Gomez-Escobar N., Nair M., Taylor M.D., Allen J.E. Helminth parasites-masters of regulation. Immunol Rev 2004, 201:89-116.